cours de bourse
14/08/2009 - 11:07:23|49.66 EUR 0.42 %
Antony, France, 11 December 2013 – STALLERGENES S.A. (Euronext Paris),...
- Stallergenes to develop and commercialize novel oral allergy drugs based...
STALLERGENES, biopharmaceutical company
Major player in its market, Stallergenes established sublingual immunotherapy and remains the world leader in this area. Since 2003, the company is committed to the Stalair® development program, creating a new therapeutic class that covers 80% of respiratory allergies.
Check out the new awareness campaign on house dust mite allergy